The impact of health technology made simple...

...from the implications of new medical procedures, technologies and policies... measuring their impact on current clinical practices...

...through close collaboration with health care professionals, researchers, and regulators.

Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.

The Vital Transformation team has:

  • Created 30 patents in stem cell technology

  • Produced regulatory applications for medicines on behalf of industry

  • Managed Bayesian modeling and health economic research harnessing Real World Data for both industries and regulators

  • Presented numerous peer reviewed publications at leading academic conferences

  • Executed branding development from ideation to website creation

  • Developed multi-stakeholder communication campaigns harnessing social media tools

Contact us to see how Vital Transformation can help you maximise your organisation’s potential.


Real world big data for clinical research and drug development

30th December, 2017

The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.


DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies

24th June, 2018, Boston, USA

Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.

Info & Registration

Find all our communication projects on Better Science, Better Health


Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

21st October, 2015

After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014.

Report: The challenges and changes needed to reengineer medicines development in the UK

9th March, 2015

A new report from the ABPI and Vermilion Life Sciences examines the challenges and changes needed for the UK to lead reengineering medicines development, and proposes a new methodology to achieve this.

TEMPEST mHealth : mHealth in 28 EU Member States

3rd November, 2014
By Wendy L. Currie and Jonathan J.M. Seddon

One of the biggest health care challenges in the coming years is how technology can be used to improve health service delivery. With the steadily increasing average life expectancy across all of Europe expected to be over 80 by 2025 and 82.5 by 2050, new and improved processes need to be delivered to meet future health requirements.



Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…

Sign Up


Our clients include many of the world’s leading health care organisations.


* required
VT Health
DGS Outlook

Click here to read our Privacy Statement.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.